European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologicals - cats - active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity after primary vaccination: 1 year.duration of immunity after revaccination: 3 years.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - feline leukaemia virus recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.onset of immunity has been demonstrated 2 weeks after primary vaccination course.the duration of immunity is one year after the last vaccination.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 virus - immunologicals, live viral vaccines equine influenza virus - horses - active immunisation of horses of four months of age or older against equine influenza to reduce clinical signs and virus excretion after infection.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 virus - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - horses - active immunisation of horses of four months of age or older against equine influenza to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) (unii: c4hqf74xmw) (rabies virus strain pm-1503-3m antigen (propiolactone inactivated) - unii:c4hqf74xmw) - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - imovax rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies. imovax rabies vaccine is approved for use in all age groups. physicians must evaluate each possible rabies exposure. local or state public health officials should be consulted if questions arise about the need for prophylaxis. (11) the following factors should be considered before antirabies prophylaxis is initiated. rabid bats have been documented in the 49 continental states, and bats are increasingly implicated as important wildlife reservoirs for variants of rabies virus transmitted to humans. transmission of rabies virus can occur from minor, seemingly underappreciated or unrecognized bites from bats (see table 2). (11) raccoons, skunks, and foxes are the terrestrial carnivores most often infected with rabies in the united states. suggestive clinical signs of rabies among wildlife cannot be interpreted reliably. all bites by such wildlife should be considered possible exposures to rabies virus. post-exposu

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim vetmedica gmbh - rabies virus - suspension for injection - live viral vaccine - cats

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rabies vaccine, wistar pm/wi 38-1503-3m 2.5 [iu] - suspension for injection - 2.5 iu - active: rabies vaccine, wistar pm/wi 38-1503-3m 2.5 [iu] excipient: albumin neomycin sulfate water for injection - post exposure immunisation against rabies. pre-exposure immunisation in persons at special risk of contracting rabies.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - rabies vaccine - suspension for injection - 2.5 iu/ml - rabies vaccines